Myopia
Pipeline by Development Stage
Ophthalmology is a $3.7B market with a mature, consolidating portfolio dominated by glaucoma treatments and emerging corneal/retinal therapies.
Key Trends
- Glaucoma therapeutics (prostaglandin analogs, adrenergic agents) represent 60%+ of spending but face patent cliffs 2028-2034
- Innovative mechanisms (NGF agonists, LFA-1 antagonists, RTKIs) gaining traction in dry eye and retinal disease segments
- Heavy trial activity (2,656 total) skewed toward Phase 4 (369) and Phase 3 (442), indicating mature clinical development landscape
Career Verdict
Ophthalmology offers stable mid-career opportunities with strong Commercial and Medical Affairs salaries, but limited innovation catalysts and significant patent cliff risk warrant careful timing of entry.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LUMIGAN (Bimatoprost) | AbbVie | $697M | 19% | LOE_APPROACHING | Declining | |
| 2 | OXERVATE (Cenegermin-BKBJ) | Unspecified | $493M | 13% | PEAK | Stable | |
| 3 | XIIDRA (Lifitegrast) | Bausch + Lomb | $473M | 13% | PEAK | Stable | 7.6yr |
| 4 | INLYTA (Axitinib) | Pfizer | $467M | 13% | PEAK | Growing | 11.2yr |
| 5 | HUMIRA (Adalimumab) | AbbVie | $258M | 7% | LOE_APPROACHING | Declining |
Drug Class Breakdown
mature, losing exclusivity
peak growth in corneal disease
sustained peak sales
expanding in retinal indications
mature, multiple LOE approaching
mature, losing exclusivity
mature immunology approach
Career Outlook
StableOphthalmology offers predictable mid-career growth with strong Commercial ($158K) and Medical Affairs ($247K) compensation but faces structural headwinds: patent cliffs 2028-2034 eliminate $97M in revenue, glaucoma franchise maturity limits blockbuster potential, and modest trial volume (2,656) signals incremental R&D expansion. Best suited for professionals seeking stable roles in established therapeutic areas rather than disruptive innovation.
Breaking In
Enter via Clinical Operations or Commercial analyst roles at CROs (Syneos 210 jobs) or large diagnostics players (Labcorp 904) to build domain expertise before targeting pharma MSL/Medical Affairs positions.
For Experienced Professionals
Experienced professionals should prioritize Medical Affairs and Market Access roles leveraging mature market knowledge; avoid product-specific expertise in glaucoma due to patent cliff concentration, and consider adjacent areas (retinal, corneal) where innovation catalysts remain.
In-Demand Skills
Best For
Hiring Landscape
Ophthalmology hiring (3,202 jobs) is distributed across diagnostics/devices (Labcorp 904, Abbott 348) and pharma commercial functions rather than concentrated in R&D. Top pharmaceutical employers (Pfizer 60, AstraZeneca 100, Regeneron 168) show modest pharma-specific headcount relative to market size, suggesting outsourced CRO and distributor dependency. Medical Affairs ($247K avg salary) commands premium compensation, signaling high barrier to entry but strong mid-career upside.
Top Hiring Companies
By Department
Clinical Operations and Commercial roles offer entry-level stability ($150K-$158K); Medical Affairs commands premium salaries ($247K) but requires advanced credentials; limited R&D hiring (207 jobs) suggests constrained innovation investment.
Competitive Landscape
30 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 49 trials with date data
Clinical Trials (50)
Total enrollment: 12,999 patients across 50 trials
Visual Outcomes and Contrast Sensitivity After Myopic LASIK
Contralateral Comparison of Three Excimer Laser Systems in Performing LASIK
Multi Laser Platform Comparison Study for LASIK
Comparative Performance of PureVision, Acuvue Oasys and O2Optix
Corneal and Conjunctival Sensitivity and Staining Study
Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK
Effects of Contact Lens Care Regimens on the Corneal Epithelium
Investigation of Multi-Purpose Solution-Based Corneal Staining and Ocular Comfort
Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)
A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children
A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
Use of a Disk of Amniotic Membrane (Visio-AMTRIX) in Postoperative Care After PKR
CHAMP: Study of NVK-002 in Children With Myopia
Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors
Safety and Efficacy Study of Topography-Guided LASIK to Treat Myopia and Hyperopia
Comparative Performance of PureVision Lens Designs
Comparison of Lens Care Regimens With a Silicone Hydrogel Lens (Emerald)
A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)
Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions
Use of the VisuMax™ Femtosecond Laser
A Study to Evaluate the Safety and Effectiveness of the 217z Laser With Zyoptix for Lasik
Efficacy of a Novel Myopia Defocus Spectacle Lens in School-Aged Children
Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy
Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life.
Association of Genetic Variants With Myopia
Evaluation of Delefilcon A Contact Lenses
Defocus-Enhanced vs. Single Vision Spectacles in Myopia Control Visual Function Training
Evaluation of Wear Experience With a Weekly Replacement Soft Contact Lens in Neophyte Lens Wearers With Astigmatism
Comparative Study of SMILE, ICL, and Wavelight Plus Alcon Technologies in Myopia Correction
DAILIES TOTAL1® Soft Contact Lenses - Post-Market Clinical Follow-up Study
Optimizing Light Exposure for Myopia Prevention and Control (LightSPAN)
Post-market Clinical Follow-up Study of Alcon PRECISION1™ Spherical and PRECISION1™ for Astigmatism Soft Contact Lenses
Euclid Phoenix Lens Design Trial 2
Visual Performance of Dailies Total1 Multifocal and Acuvue Oasys Max 1-Day Multifocal in Presbyopic Lens Wearers
A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
Comparison of Clinical Performance of Two Monthly Replacement Toric Soft Contact Lenses
Characterization of the Central and Peripheral Wavefront Aberration Profile in Pediatric Myopic Subjects
Kubota Glass Parameter Refinement Study
Euclid Phoenix Lens Design Trial
Clinical Assessment of a Daily Disposable Soft Silicone Hydrogel Contact Lens
Air Optix® Night and Day® Aqua Continuous Wear
Air Optix® Night and Day® Aqua Daily Wear
Electronic Spectacles Versus Low Dose Atropine in Young Myopes
Air Optix® Night and Day® Aqua Therapeutic Wear
Air Optix Plus HydraGlyde Multifocal Daily/Extended Wear Contact Lenses
Air Optix Extended Wear Contact Lenses
Air Optix Daily Wear Contact Lenses
Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in the Arise Orthokeratology Lens
Clinical Comparison of Toric Contact Lenses Fit Characteristics
Related Jobs in Ophthalmology
AI Product Manager
Sr Engineer II, Machine Learning
Senior Quality Engineer
Research Associate/Senior Research Associate, In Vivo Pharmacology
Senior Manager, Global Logistics
Senior Manufacturing Engineer (Laser Welding)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.